Why is Quest Laboratories Ltd falling/rising?

Recent Price Movement and Market Comparison

On 19 January, Quest Laboratories Ltd’s shares declined by ₹2.10, or 2.08%, closing at ₹99.00. This drop is part of a broader downward trend, with the stock falling 3.46% over the past week and nearly 9% in the last month. Year-to-date, the stock has declined by over 10%, significantly underperforming the Sensex, which has only dipped by 2.08% in the same period. Over the last year, the contrast is even starker: while the Sensex has gained 10.27%, Quest Laboratories has lost 23.85% of its value.

Such underperformance is notable given the company’s sector and market conditions, where many peers have managed to sustain or grow their valuations. The stock’s relative weakness suggests that investors are factoring in company-specific concerns rather than broader market trends.

Technical Indicators and Trading Activity

From a technical perspective, the stock is trading above its 50-day, 100-day, and 200-day moving averages, indicating a generally positive long-term trend. However, it remains below its 5-day and 20-day moving averages, signalling short-term weakness. This divergence suggests that while the stock has underlying strength, recent momentum has faltered.

Investor participation has also diminished sharply. Delivery volume on 16 January was just 3,600 shares, down by 81.25% compared to the five-day average delivery volume. This significant drop in trading activity points to waning investor interest or hesitation, which often precedes price declines. Despite this, liquidity remains adequate for trading, with the stock able to handle sizeable trade volumes without excessive price impact.

Fundamental Strengths Amidst Profitability Concerns

Quest Laboratories boasts several positive financial attributes. The company demonstrates high management efficiency, reflected in a robust Return on Capital Employed (ROCE) of 34.54%. Its low average debt-to-equity ratio of 0.09 times indicates a conservative capital structure, reducing financial risk. Operating profit has grown at an impressive annual rate of 36.74%, signalling healthy long-term growth prospects. Additionally, the company’s Return on Equity (ROE) stands at 15.1%, and it trades at an attractive Price to Book Value of 1.8, suggesting reasonable valuation relative to its net assets.

Despite these strengths, the stock’s profitability metrics have raised concerns. Over the past year, while profits have increased by 34%, the stock price has declined by nearly 24%. This disconnect may reflect investor scepticism about the sustainability of earnings growth or other operational challenges.

Recent Quarterly Performance and Market Sentiment

The company’s latest quarterly results, reported for September 2025, showed flat performance. Net sales for the quarter stood at ₹25.62 crore, down 8.7% compared to the average of the previous four quarters. Moreover, non-operating income accounted for 35.32% of profit before tax, indicating that a significant portion of earnings is derived from sources outside core operations. This reliance on non-operating income may raise questions about the quality and sustainability of profits.

These factors have contributed to the stock’s underperformance relative to the broader market. While the BSE500 index has generated returns of 7.53% over the last year, Quest Laboratories has lagged considerably, reflecting investor concerns about growth consistency and earnings quality.

Conclusion: Balancing Strengths and Weaknesses

In summary, Quest Laboratories Ltd’s share price decline as of 19 January is driven by a combination of factors. While the company exhibits strong management efficiency, low leverage, and solid long-term profit growth, recent quarterly sales contraction and a heavy reliance on non-operating income have dampened investor enthusiasm. The stock’s persistent underperformance relative to market benchmarks and reduced trading volumes further underscore cautious sentiment.

Investors should weigh the company’s attractive valuation and operational strengths against the risks posed by recent earnings volatility and market underperformance. The current price action reflects this complex interplay, resulting in a downward trend despite promising fundamentals.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →